Therapeutic effect of an anti-human-TNF-alpha antibody and itraconazole on feline infectious peritonitis

Arch Virol. 2020 May;165(5):1197-1206. doi: 10.1007/s00705-020-04605-7. Epub 2020 Mar 31.

Abstract

Feline infectious peritonitis (FIP) is a fatal disease in wild and domestic cat species. Although several drugs are expected to be useful as treatments for FIP, no drugs are available in clinical practice. In this study, we evaluated the therapeutic effect of combined use of adalimumab (an anti-human-TNF-alpha monoclonal antibody, ADA) and itraconazole (ICZ), which are presently available to veterinarians. The neutralizing activity of ADA against fTNF-alpha-induced cytotoxicity was measured in WEHI-164 cells. Ten specific pathogen-free (SPF) cats were inoculated intraperitoneally with type I FIPV KU-2. To the cats that developed FIP, ADA (10 mg/animal) was administered twice between day 0 and day 4 after the start of treatment. ICZ (50 mg/head, SID) was orally administered daily from day 0 after the start of treatment. ADA demonstrated dose-dependent neutralizing activity against rfTNF-alpha. In an animal experiment, 2 of 3 cats showed improvements in FIP clinical symptoms and blood chemistry test results, an increase in the peripheral blood lymphocyte count, and a decrease in the plasma alpha 1-AGP level were observed after the beginning of treatment. One of the cats failed to respond to treatment and was euthanized, although the viral gene level in ascites temporarily decreased after the start of treatment. ADA was found to have neutralizing activity against rfTNF-alpha. The combined use of ADA and ICZ showed a therapeutic effect for experimentally induced FIP. We consider these drugs to be a treatment option until effective anti-FIPV drugs become available.

MeSH terms

  • Adalimumab / administration & dosage*
  • Animals
  • Cats
  • Drug Therapy, Combination / methods
  • Feline Infectious Peritonitis / pathology
  • Feline Infectious Peritonitis / therapy*
  • Immunologic Factors / administration & dosage*
  • Immunotherapy / methods
  • Itraconazole / administration & dosage*
  • Treatment Outcome

Substances

  • Immunologic Factors
  • Itraconazole
  • Adalimumab